Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $1.3 billion.

  • Ascendis Pharma A's Liabilities and Shareholders Equity rose 1238.35% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 billion, marking a year-over-year increase of 3124.57%. This contributed to the annual value of $1.3 billion for FY2024, which is 4371.7% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Liabilities and Shareholders Equity of $1.3 billion as of Q3 2025, which was up 1238.35% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Liabilities and Shareholders Equity ranged from a high of $2.3 billion in Q4 2021 and a low of $816.6 million during Q2 2024
  • For the 5-year period, Ascendis Pharma A's Liabilities and Shareholders Equity averaged around $1.2 billion, with its median value being $1.2 billion (2021).
  • In the last 5 years, Ascendis Pharma A's Liabilities and Shareholders Equity surged by 6973.81% in 2021 and then crashed by 5135.94% in 2022.
  • Ascendis Pharma A's Liabilities and Shareholders Equity (Quarter) stood at $2.3 billion in 2021, then plummeted by 51.36% to $1.1 billion in 2022, then fell by 20.1% to $888.3 million in 2023, then soared by 41.89% to $1.3 billion in 2024, then rose by 7.11% to $1.3 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.3 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.1 billion in Q1 2025.